高危心源性休克患者使用高流量Impella轴流泵的临床结局:CSWG报告
基于美国34家医院CSWG注册研究,2020-2023年6205例心源性休克患者中754例(12.1%)接受Impella 5.0/5.5支持,出院生存率67%,20.4%自体心脏恢复、45.5%接受心脏替代治疗;心梗相关休克较心衰相关休克院内死亡率更高(45.2% vs 26.2%),联合其他tMCS者不良事件和死亡率更高。
要点
- Impella 5.0/5.5单用者占32%,联合其他tMCS者占68%。
- 出院生存率67%,自体心脏恢复20.4%,心脏替代治疗45.5%。
- 心梗相关休克院内死亡率45.2%,高于心衰相关休克的26.2%。
核心结论
- 在多中心心源性休克队列中,使用Impella 5.0/5.5与67.1%的总体生存率及较高的心脏替代治疗率相关。
- 当Impella 5.0/5.5作为唯一支持装置时,观察到较低的不良事件发生率。
- 需进一步研究明确早期使用Impella 5.0/5.5的策略是否改善心源性休克生存。
研究设计与样本
- CSWG注册研究纳入美国34家医院的患者,分析2020-2023年间接受Impella 5.0/5.5的6205例中的754例(12.1%)。
- 研究Impella 5.0/5.5单用或联合其他tMCS的支持时长、不良事件及出院结局。
- 不良事件包括卒中、肢体缺血、出血和溶血,未由注册研究标准化,由各中心主要研究者酌情报告。
主要发现
- 754例中,心梗相关休克210例(27.8%),心衰相关休克484例(64.1%)。
- Impella 5.0/5.5单用者占32%,联合其他tMCS者占68%。
- 出院生存率67%,自体心脏恢复20.4%,心脏替代治疗45.5%。
- 心梗相关休克较心衰相关休克院内死亡率更高(45.2% vs 26.2%,p < 0.001),接受心脏替代治疗更少(22.4% vs 56.6%,p < 0.001)。
- 联合tMCS者较单用Impella 5.0/5.5者肢体缺血(9% vs 3%,p < 0.01)、出血(52% vs 33%,p < 0.01)和死亡率(38% vs 25%,p < 0.001)更高。
关键数值与推荐
- Impella 5.0/5.5置管部位数据 available for 524/754(69.4%),其中93.5%为腋动脉配置。
- 泵支持中位时长12.9天(IQR:6.8-22.9),桥接至心脏替代治疗者更长(14天;IQR:7.7-28.4)。
临床怎么用
- 在真实世界心源性休克患者中,Impella 5.0/5.5可用于提供高流量临时机械循环支持。
- 心梗相关休克患者使用Impella 5.0/5.5时院内死亡率较高、接受心脏替代治疗较少。
- 联合其他tMCS装置与更高的肢体缺血、出血和死亡率相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Impella 5.0 and 5.5 pumps (Abiomed, Danvers, MA) are large-bore transvalvular micro-axial assist devices used in cardiogenic shock (CS) for patients requiring high-capacity flow. Despite their increasing use, real-world data regarding indications, rates of utilization and clinical outcomes with this therapy are limited. The objective of our study was to examine clinical profiles and outcomes of patients in a contemporary, real-world CS registry of patients who received an Impella 5.0/5.5 alone or in combination with other temporary mechanical circulatory support (tMCS) devices. METHODS: The CS Working Group (CSWG) Registry includes patients from 34 US hospitals. For this analysis, data from patients who received an Impella 5.0/5.5 between 2020-2023 were analyzed. Use of Impella 5.0/5.5 with or without additional tMCS therapies, duration of support, adverse events and outcomes at hospital discharge were studied. Adverse events including stroke, limb ischemia, bleeding and hemolysis were not standardized by the registry but reported per individual CSWG Primary Investigator discretion. For those who survived, rates of native heart recovery (NHR) or heart replacement therapy (HRT) including heart transplant (HT), or durable ventricular assist device (VAD) were recorded. We also assessed outcomes based on shock etiology (acute myocardial infarction or MI-CS vs. heart failure-related CS or HF-CS). RESULTS: Among 6,205 patients, 754 received an Impella 5.0/5.5 (12.1%), including 210 MI-CS (27.8%) and 484 HF-CS (64.1%) patients. Impella 5.0/5.5 was used as the sole tMCS device in 32% of patients, while 68% of patients received a combination of tMCS devices. Impella cannulation sites were available for 524/754 (69.4%) of patients, with 93.5% axillary configuration. Survival to hospital discharge for those supported with an Impella 5.0/5.5 was 67%, with 20.4% NHR and 45.5% HRT. Compared to HF-CS, patients with MI-CS supported on Impella 5.0/5.5 had higher in-hospital mortality (45.2% vs 26.2%, p < 0.001) and were less likely to receive HRT (22.4% vs 56.6%, p < 0.001. For patients receiving a combination of tMCS during hospitalization, this was associated with higher rates of limb ischemia (9% vs. 3%, p < 0.01), bleeding (52% vs 33%, p < 0.01), and mortality (38% vs 25%; p < 0.001) compared to Impella 5.0/5.5 alone. Among Impella 5.0/5.5 recipients, the median duration of pump support was 12.9 days (IQR: 6.8-22.9) and longer in patients bridged to HRT (14 days; IQR: 7.7-28.4). CONCLUSIONS: In this multi-center cohort of patients with CS, use of Impella 5.0/5.5 was associated with an overall survival of 67.1% and high rates of HRT. Lower adverse event rates were observed when Impella 5.0/5.5 was the sole support device used. Further study is required to determine whether a strategy of early Impella 5.0/5.5 use for CS improves survival. CONDENSED ABSTRACT: High capacity Impella heart pumps are capable of provide up to 5.5 liter/min of flow while upper body surgical placement allows for ambulation. Patients with advanced cardiogenic shock from acute myocardial infarction or heart failure requiring temporary mechanical circulatory support may benefit from upfront use of Impella 5.5 to improve overall survival, including native heart recovery or successful bridge to durable left ventricular assist device surgery or heart transplantation.
引用
- Fried J, Farr M, Kanwar M, et al. Clinical outcomes among cardiogenic shock patients supported with high-capacity Impella axial flow pumps: A report from the Cardiogenic Shock Working Group. J Heart Lung Transplant. 2024. PMID: 38834162. doi:10.1016/j.healun.2024.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。